Recruitment process for new CFO is underway
Solna, Sweden, 3 March 2022 – Oasmia Pharmaceutical AB, hereby announces that Fredrik Järrsten will step down from his position as CFO later this year after serving his six-month notice period in order to pursue new opportunities. The process of appointing a new CFO has begun. Fredrik will continue to support the company for the next six months until a new CFO is appointed.
Francois Martelet, CEO of Oasmia commented: “Fredrik has played an important part in the transformation of Oasmia to become down the road a Nordic oncology powerhouse. He has played an important role in building the finance team, bringing our costs under control, and strengthening our financial position. We are now well positioned to transition to a successful future as Vivesto and we look forward to appointing a new CFO to support us on the next step in our journey. We wish Fredrik all the best for his future endeavours and thank him for his contribution.”
For More Information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.